Evidence map›Paper›PMID 27034822›Full record

ArticleJournal of ophthalmology2016

A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.

Xiaochun Yang, Jianbiao Xu, Ruili Wang, Yan Mei, Huo Lei, Jun Liu, Ting Zhang, Haiyan Zhao

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05414149 (Efficacy and Safety Comparison of Ranibizumab and Conbercept Pretreatment Before Vitrectomy in Proliferative Diabetic Retinopathy), which is not on this map. Cited by 29 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 6 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05414149 nacompletednot on this mapstarted 2021, after this paper: background citation

Efficacy and Safety Comparison of Ranibizumab and Conbercept Pretreatment Before Vitrectomy in Proliferative Diabetic Retinopathy

TypeinterventionalSponsorPeking University People's HospitalRan2021 to 2022Enrolled80ConditionsProliferative Diabetic RetinopathyArmspreoperative intravitreal injections of ranibizumab or conbercept
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 6 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiaochun YangDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
Jianbiao XuDepartment of General Surgery, The First People's Hospital of Yunnan Province, Yunnan 650032, China.ORCID 0000-0003-4769-8664
Ruili WangDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
Yan MeiDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
Huo LeiDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.ORCID 0000-0002-4009-6970
Jun LiuDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
Ting ZhangState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong 510062, China.
Haiyan ZhaoDepartment of Ophthalmology, The First People's Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, China.
Kunming University of Science and Technology · CNFirst People's Hospital of Yunnan Province · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels. The secondary safety measures included intraocular pressure, endophthalmitis, rubeosis, tractional retinal detachment, and systemic adverse events. Results. The incidence and severity of intraoperative bleeding were significantly lower in IVC group than in the control group. The average vitreous clear-up time of early recurrent VH was significantly shorter in IVC group compared with that in control group. There was no significant difference in vitreous clear-up time of late recurrent VH between the two groups. Patients that received pretreatment of conbercept had much better BCVA at 3 days, 1 week, and 1 month after surgery than control group. Moreover, both patients with improved BCVA were greater in IVC group than in control group at each follow-up. Conclusions. Conbercept pretreatment could be an effective adjunct to vitrectomy in accelerating postoperative vitreous clear-up and acquiring stable visual acuity restoration for PDR.

Identifiers

PMID27034822
PMCPMC4808544
OpenAlexW2301215147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.